DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
darlings - 1 Brian Szytel - 1 Szytel - 1 Goldman Sachs - 1 Baker Hughes - 1 Properties - 1 Tim Sheehy - 1 Democratic Sen - 1
Top related locs:
Montana Bridger Rick Scott of Florida Rosendale China PZIEX Cloverly Basel
Top related orgs:
Royalty Pharma - 3 Group - 1 CNBC - 1 Vanguard - 1 AES Corporation - 1 Halliburton Company - 1 AES - 1 Service - 1

Search resuls for: "Royalty Pharma"


5 mentions found


☆ Analysts love these value stocks, giving 4 more than 30% upside
  + stars: | 2024-03-07 | by ( Weizhen Tan | ) www.cnbc.com   time to read: +2 min
Growth stocks have often been investor darlings — the S & P 500 is driven by stocks in sectors like tech. Value stocks are less popular. But many growth stocks are also becoming expensive, prompting some investors to turn to value stocks. Goldman Sachs also recently highlighted value stocks that stand out for their cheap valuations compared with earnings growth prospects. Those interested in value stocks can consider the following from CNBC Pro's screen of the Vanguard Value ETF.
Persons: darlings, Brian Szytel, Szytel, Goldman Sachs, Baker Hughes, Properties Organizations: Group, CNBC, Vanguard, AES Corporation, Halliburton Company, AES, Royalty Pharma
☆ Montana GOP Senate candidate would be in the top 10 richest lawmakers — and his investments are sure to irk some conservatives
  + stars: | 2023-11-02 | by ( Bryan Metzger | ) www.businessinsider.com   time to read: +5 min
Tim Sheehy, GOP leadership's anointed Senate candidate in Montana, disclosed his personal finances. Altogether, the Montana Republican's net worth lies somewhere between $74 million and $260 million, according to a calculation of his declared assets. Yet Tester still handily outraised Sheehy during the last quarter, raising $5 million versus Sheehy's $2.8 million. The Montana Republican and his wife are also invested in a variety of pharmaceutical companies, even as skepticism of big pharma grows on the right in the wake of the pandemic and COVID-19 vaccine mandates. The spokesperson also pointed to Sheehy's ethics pledge, which states that the Montana Republican will place all of his stocks into a blind trust if elected.
Persons: Tim Sheehy, Democratic Sen, Jon Tester, Bridger Aerospace CEO's, Republican Sen, Rick Scott of, who's, Tester, outraised Sheehy, Matt Rosendale, —, Sheehy, Bridger Organizations: Service, Democratic, Bridger Aerospace, Republican, Bridger, GOP, Montana Republican, Johnson, Royalty Pharma Locations: Montana, Bridger, Rick Scott of Florida, Rosendale, China, PZIEX, Cloverly
☆ Royalty Pharma to pay $1 bln for Roche's SMA drug royalties
  + stars: | 2023-10-19 | by ( ) www.reuters.com   time to read: +1 min
The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing RightsOct 19 (Reuters) - Royalty Pharma (RPRX.O) said on Thursday it has purchased additional royalties on Roche (ROG.S) and PTC Therapeutics' (PTCT.O) oral spinal muscular atrophy (SMA) drug for an upfront payment of $1 billion. Spinal muscular atrophy, a leading genetic cause of infant deaths, prevents the body from producing a protein necessary for neuromuscular development. The deal also includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million at a later date, Royalty Pharma said. Royalty Pharma expects to fund the transaction with a combination of existing cash and about $350 million from its revolving credit facility.
Persons: drugmaker Roche, Arnd, Roche, Mariam Sunny, Shilpi Majumdar Organizations: REUTERS, Royalty Pharma, PTC Therapeutics, U.S . Food, Drug Administration, PTC, Thomson Locations: Basel, Switzerland, Bengaluru
☆ Roche's Alzheimer's drug fails to meet goal in long awaited trial
  + stars: | 2022-11-14 | by ( Ludwig Burger | ) www.reuters.com   time to read: +4 min
Nov 14 (Reuters) - Roche said (ROG.S) its Alzheimer's drug candidate could not clearly be shown to slow dementia progression in two drug trials, failing to draw level with a recent development success by rivals Biogen (BIIB.O) and Eisai (4523.T). Within each study, volunteers were randomly assigned to receive either the injectable antibody drug gantenerumab or a placebo. The quest to develop an Alzheimer's drug, targeting beta-amyloid or other molecules, has been beset by a long list of study failures. But rival Biogen in September scored a surprise trial success with an experimental Alzheimer's drug that it developed with Eisai, rebuilding confidence among industry executives and researchers in the beta-amyloid approach. Schwan earlier this year sought to curb expectations for the Graduate trials but the head of Roche's pharma unit last month acknowledged that Biogen's success with lecanemab had reignited hopes.
☆ Cramer's lightning round: You are fighting the Fed with Discover Financial
  + stars: | 2022-10-13 | by ( Krystal Hur | ) www.cnbc.com   time to read: 1 min
Discover Financial Services : "You are fighting the Fed with DFS. I think the ag group is ready to roll again, as in bull market mode." Loading chart...Royalty Pharma PLC : "I like it, and I'm going to stick with it. Loading chart...Tellurian Inc : "It's at $2, and stocks stop at $0. Loading chart...Zoetis Inc : "I think the stock is now undervalued.
0 next >>
Total: 5